Recruiting

Observational Study

Sponsor:

University of Vermont

Code:

NCT06692894

Conditions

Myelodysplastic Syndromes, Adult

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Observational

Study Details

Brief summary:

Why Is This Research Study Being Conducted?

  • The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke.
  • Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients.
  • By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS

Conditions

Myelodysplastic Syndromes, Adult

Study ID

NCT06692894

Start date

Nov 5, 2024

Status verified date

Feb, 2026

Completion date

Nov, 2027

Anticipated

Primary completion date

Nov, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥18 years
  • Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤3
  • Expected survival of at least 6 months
  • Ability to provide consent

Exclusion Criteria:

  • Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
  • Hematopoietic stem cell transplantation expected within 6 months

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Adults with Myelodysplastic syndromes

All participants will be in one group. Participants will by adults with Myelodysplastic syndromes. Blood will be taken at regular appointments that are part of standard care.

Interventions

Observational

Blood will be collected from one cohort to identify potential blood biomarkers.

Primary outcome measure

  • Biologic Variability of Markers of Inflammation in the Blood [ Time Frame: over 6 months ]

Central Contacts and Locations

Central contacts

Diego Adrianzen Herrera, MD

(802) 656-2021dadrianz@med.uvm.edu

Neil A Zakai, MD

(802) 656-2021neil.zakai@med.uvm.edu

Locations

University of Vermont

Recruiting

Burlington, Vermont, United States, 05495-2038

Contacts

Diego Adrianzen Herrera, MD

(802) 656-4414dadrianz@uvm.edu

Principal Investigator:

Diego Adrianzen Herrera, MD

More Information

Sponsor

University of Vermont

Last update posted

Feb 3, 2026

Last verified

Feb, 2026

Keywords

  • Myelodysplastic Syndromes
  • Hematology

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Vermont on 2026-02-03.